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Abstract
Background: The majority of patients with idiopathic pulmonary arterial hypertension (IPAH) in functional classes II
and III are currently being treated with non-parenteral therapies, including endothelin receptor antagonists (ERA),
phosphodiesterase (PDE)-5 inhibitors, inhaled iloprost or combinations of these substances. If these treatments fail,
current guidelines recommend the addition of parenteral prostanoid therapy. There is, however, limited evidence
for the efficacy of parenteral prostanoids when added to combinations of non-parenteral therapies.
Methods: In this retrospective, multicentre study we collected data from consecutive IPAH patients receiving
intravenous iloprost in addition to optimized non-parenteral therapy between Jan 2002 and Dec 2009. Analyses
included 6 min walk distance (6MWD), functional class, need for transplantation, and survival.
Results: During the observation period, 50 patients were treated with intravenous iloprost in addition to non-
parenteral therapy; 44% of the patients were on dual combination therapy and 52% on triple combination. Three
months after initiation of iloprost, functional class had improved in 24% of the patients and the median 6MWD
had increased from 289 m to 298 m (n.s.). During the observation period, 22 patients (44%) died and 14 (28%)
underwent lung transplantation. The probabilities of LuTx-free survival at 1, 3 and 5 years following iloprost
initiation were 38%, 17% and 17%, respectively. A 6MWD < 300 m and persistent functional class IV at 3 months
after initiation of intravenous iloprost were predictors of an adverse outcome.
Conclusion: In essence, late initiation of intravenous iloprost in IPAH patients who previously failed to respond to
non-parenteral therapies appears to be of limited efficacy in the majority patients. Alternative therapeutic options
are currently not available, underlying the need for the development of new drugs.
Background
Less than 10 years ago, intravenous epoprostenol was
the standard treatment for patients with idiopathic pul-
monary arterial hypertension (IPAH). The first intrave-
nous prostanoid studied in patients with IPAH,
epoprostenol is still the only drug for which improved
survival in treatment-naive patients with advanced IPAH
has been demonstrated [1]. Newer prostanoids used for
intravenous therapy are treprostinil and iloprost [2-5]. It
is unclear whether the efficacy of both drugs is compar-
able to epoprostenol as this has not yet been formally
evaluated in randomized placebo controlled or head-to-
head comparison trials. The need for parenteral admin-
istration, however, is a major drawback for all of these
drugs.
In recent years, non-parenteral therapies, especially
endothelin receptor antagonists (ERAs), phosphodiester-
ase (PDE)-5 inhibitors and inhaled prostanoids have
replaced intravenous prostanoids as preferred initial
therapies for patients presenting in functional classes II
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used in patients presenting with advanced disease or
when the less invasive therapies have been exhausted,
respectively.
If patients deteriorate while receiving optimized non-
parenteral therapies it is advocated to add an intrave-
nous prostanoid [11] although this approach has not
undergone the scrutiny of carefully conducted clinical
trials. In the present study we investigated the long-
term effects of adding intravenous iloprost to oral thera-
pies in patients with severe IPAH.
Methods
The present study was performed at 7 German pulmon-
ary hypertension referral centres. Data were collected
retrospectively from consecutive adult patients with
IPAH who had received intravenous iloprost in addition
to optimized oral therapies (PDE-5 inhibitor and/or
ERA) between Jan 1
st 2002 and Dec 31
st 2009. Oral
therapy was a requirement for inclusion, whereas addi-
tional therapy with inhaled iloprost was facultative. Fol-
low-up ended March 31
st 2010. Patients with other
forms of pulmonary hypertension were excluded. This
analysis was approved by the institutional review boards
of the participating centres and all patients gave written
informed consent.
There was no overlap between the present patient
population and the patients reported in an earlier paper
on the effects of intravenous iloprost in patients failing
inhaled iloprost therapy, as in the prior study, patients
were not pre-treated with an ERA or PDE-5 inhibitor
and initiation of intravenous iloprost was between 1997
and 2001 [3].
Data on hemodynamics, functional class and 6 min
walking distance (6MWD) were collected from different
time points: (i) the initial assessment at the time of diag-
nosis, (ii) the last assessment prior to initiation of intra-
venous iloprost therapy (baseline iloprost; BL-Ilo), (iii) 3
and (iv) 12 months thereafter. Hemodynamic data from
right heart catheterization were obtained from all
patients at the time of diagnosis, i.e. prior to initiation
of PAH-targeted therapy. For the assessment of hemo-
dynamics prior to BL-Ilo, catheter data were only con-
sidered when they were not older than 3 months.
The patients enrolled in this analysis were treated
according to local standards with respect to oxygen-sup-
plementation, diuretics, anticoagulation and non-parent-
eral therapies with ERAs, PDE-5 inhibitors and inhaled
iloprost.
There were no predefined criteria for the initiation for
intravenous iloprost treatment. Decisions on start,
dosage and up-titrations as well as follow-up visits were
made by the responsible physicians at the participating
centres. All patients were hospitalized for initiation of
therapy. Iloprost was diluted in saline to a volume of
100 ml and administered via a port- or Hickman-cathe-
ter using a portable pump (CADD-1; Deltec, St. Paul,
MN, USA). The medication was prepared under sterile
conditions by specialized pharmacists and delivered to
the patients’ homes. The cassettes containing the medi-
cation were replaced every 48 hrs. The iloprost dose
was titrated according to individual tolerability and clin-
ical effects. The general aim was to reach the highest
tolerated dose of intravenous iloprost.
Statistical evaluation
Data were collected on Microsoft office Excel 2007
spreadsheets. Survival analyses were carried out using
GraphPad PRISM 5.0 for Windows (GraphPad Software
Inc., Software MacKiev).
Pairwise statistical comparisons between baseline para-
meters at diagnosis (Dx) and BL-Ilo were performed
using a t-test if the data were normally distributed
according to the Kolmogorov-Smirnov-test. Otherwise a
nonparametric U-test was carried out. To compare the
data obtained at month 3 and 12 of intravenous iloprost
therapy with those obtained at BL-Ilo, multiple compari-
sons were performed by repeated one-way ANOVA fol-
lowed by Tukey’s correction for multiple comparisons.
Kaplan-Meier curves were plotted for overall survival
with censoring of patients who had undergone lung
transplantation (LuTx) and for LuTx-free survival (i.e.,
combined endpoint, death or transplantation; Tx-free
survival). Survival analyses were performed from the
time of diagnosis and from the time when intravenous
iloprost therapy was started.
The probability of survival for each patient at the time
t after diagnosis was calculated applying the National
Institute of Health (NIH) equation [12,13].
p(t) =H (t)
A(x,y,z).
H(t) was defined by the time t via H(t) = 0.88-0.14t
+0.01t
2 and A(x, y, z) could be calculated from the
results of the RHC: A(x, y, z) = e
0.007325x+0.0526y-0.3235z,
where x was the mean pulmonary arterial pressure
(PPA), y was the mean right atrial pressure (PRA)a n dz
was the cardiac index (CI). The expected value for each
patient to be alive at different time points was deter-
mined and the expected Kaplan-Meier curve was plotted
a n dc o m p a r e dt ot h eo b s e r v e dK a p l a n - M e i e rs u r v i v a l
curves for overall survival and LuTx-free survival. A log-
rank test (= Mantel-Cox test) was performed to com-
pare the observed and expected survival curves for sig-
nificant differences.
In order to identify risk factors for an adverse out-
come (death or LuTx), an univariate Cox-regression
analysis was performed using the time interval between
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variable at the median, hemodynamic parameters, func-
tional class and 6 min walking distance at BL-Ilo and 3
months later (SPSS version 18.0, Inc., Chicago, Illinois,
USA).
Depending on functional class (III or better vs. IV)
and the 6MWD (cut-off 300 m) at 3 months, Kaplan-
Meier survival curves of subgroups were plotted and
compared, using a log-rank test (Mantel-Cox test). The
cut-off of 300 m was chosen as this value was close to
the median of 298 m 3 month after BL-ilo.
A correlation analysis comparing dosages of Iloprost
at 3 months and changes in 6MWD was performed
using the Spearman test.
Results are shown as median and interquartile range
(IQR), unless stated otherwise. A p-value < 0.05 was
considered statistical significant for all analyses.
Results
Between January 1
st 2002 and December 31
st 2009, fifty
patients with IPAH were treated with intravenous ilo-
prost in addition to optimized non-parenteral therapy
(see Table 1 for details). The median interval between
diagnosis and BL-Ilo was 34 months, ranging from 1 to
104 months. Compared to the time of diagnosis, at BL-
Ilo there was a deterioration in functional class and a
significant decrease in the 6MWD (Table 1).
Hemodynamic assessment demonstrated a significant
increase in PRA while the remaining hemodynamic para-
meters were virtually unchanged (Table 1).
The majority of patients (78%) received oral medica-
tions (sildenafil, an ERA or a combination of sildenafil
and ERA) as first-line therapies; 16% started monother-
apy on inhaled iloprost and 6% a combination of sildena-
fil and inhaled iloprost. At BL-Ilo, all patients received at
least one oral agent, i.e. an ERA or sildenafil, and the
majority of patients (80%) were receiving a combination
of both substances. Forty-three patients (86%) received
sildenafil at a median dose of 150 mg/d (IQR, 100-180
mg/d). Forty-seven patients (94%) received an ERA, 36
bosentan, 9 sitaxentan and 2 ambrisentan at median daily
dosages of 250 mg, 100 mg and 10 mg, respectively. In
addition, 68% of the patients were treated with inhaled
iloprost (30 μg per day). Hence, at BL-Ilo, 52% of the
patients were receiving triple combination therapy and
another 44% double combination therapy (Table 1).
Oral therapies were continued in all cases when intra-
venous iloprost was started. At that point in time
inhaled iloprost was withdrawn in 14 patients and con-
tinued in the remaining 20 patients.
The median dose of intravenous iloprost was 1.73 ng/
min/kg (IQR, 1.14-2.18 ng/min/kg) after 3 months and
1.80 ng/min/kg (IQR, 1.20-2.40 ng/min/kg) after 12
months, respectively.
Table 1 Patient characteristics
Time point Dx Last measurement prior to start of IV iloprost
Subjects (n) 50 50
Age (years) 42 (29-58) 44 (31-63)
Interval diagnosis and initiation of iloprost (month) 34 (20-47)
Female/male 34/16 34/16
NYHA class II/III/IV 7/30/13 1/24/24
6MWD (m) 332 (229-434) 289 (132-370)
#
PAH-specific therapy Initial therapy
Sildenafil alone 11 (22%) 0 (0%)
ERA alone 22 (44%) 2 (4%)
Inhaled Iloprost alone 8 (16%) 0 (0%)
Sildenafil + ERA 6 (12%) 14 (28%)
Sildenafil + inhaled Iloprost 3 (6%) 3 (6%)
ERA + inhaled Iloprost 0 (0%) 5 (10%)
Triple therapy 0 (0%) 26 (52%)
Hemodynamics n = 50 n = 26
PRA (mmHg) 7 (3-13) 12 (7-16)
#
Ppa (mmHg) 59 (48-68) 56 (49-65)
Ppcw (mmHg) 7 (5-9) 9 (7-11)
CI (L/min/m
2) 2.0 (1.5-2.3) 1.7 (1.4-1.9)
PVR (dyn*s*cm
-5) 1, 251 (852-1, 705) 1, 205 (954-1, 499)
SVO2 (%) 58 (54-66) 58 (54-69)
Characteristics at diagnosis (Dx) and start of intravenous iloprost. Absolute values are given regarding PAH-specific therapy, functional class and gender. Age,
interval from Dx to BL-ilo, 6MWT and hemodynamic parameters are given as median (interquartile range; IQR). #: p < 0.05 vs Dx.
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A tt h et i m eo fd i a g n o s i s ,1 4 %o ft h ep a t i e n t sw e r ei n
functional class II, 60% in functional class III and 26%
in functional class IV. At BL-Ilo, one patient (2%) was
in functional class II, while 49% each were in functional
class III and IV, respectively.
Three months after iloprost was started, 7 patients
had died and 3 had undergone LuTx. Functional class
data were available from 38 out of the remaining 40
patients. Nine of these patients (24%) showed an
improvement in functional class. Two patients (5%)
deteriorated from functional class III to functional class
IV and 27 patients (71%) remained in the pre-treatment
functional class.
At 12 months after BL-Ilo, 18 patients (36%) had died
and 10 (20%) had undergone LuTx. Sixteen patients
were within the observational period. Compared to the
assessment done at BL-Ilo, none of the remaining 16
patients showed further improvement of the functional
class; two patients had deteriorated from class III to IV
and 14 remained in the same class as before.
Effect of intravenous iloprost therapy on 6 min walking
distance
Individual data on 6MWD are shown in Figure 1. Those
data were available for 37 patients at BL-Ilo. After 3 and
1 2m o n t h s ,6 M W Dd a t aw e r ea v a i l a b l ef r o m2 8a n d1 3
patients, respectively. Compared to BL-Ilo, the median
6MWD increased slightly after 3 months of therapy
from 289 m (IQR, 132-370 m) to 298 m (IQR, 189-171
m). For those patients for which 6MWD were available
after 12 months, there was a further increase to 345 m
(IQR, 231-422 m); however, none of these changes were
statistically significant. No significant correlation was
found between the dosage of intravenous iloprost and
the change in 6MWD at 3 months compared to BL-Ilo
(r = 0.33, p = 0.08; data not shown).
Survival and lung transplantation
During the observation period, 22 patients (44%) died and
14 (28%) underwent lung transplantation. Fourteen
patients (28%) survived until the end of the study. The
median LuTx-free survival was 45 months (IQR, 30-92
months) from the time of diagnosis and 9 months (IQR,
4-25 months) from BL-Ilo. The median overall survival
(patients undergoing LuTx censored at the time of trans-
plantation) was 87 months (IQR, 39-109 months) after
diagnosis and 15 months (IQR, 7-76 months) after BL-Ilo.
Comparison of expected and observed survival after
diagnosis
Figure 2 shows the observed LuTx-free (Figure 2a) and
the observed overall survival (Figure 2b) after diagnosis
as well as the expected survival as derived from the NIH
registry equation [12]. The observed median LuTx-free
survival and the overall survival after diagnosis were 45
and 87 months, respectively. The expected median sur-
vival after diagnosis was 30 months which was signifi-
cantly lower than the observed overall survival (p <
0.01). The observed LuTx-free survival rates 1, 2, 3, 4, 5
and 6 years after diagnosis were 96%, 86%, 68%, 46%,
37% and 34% respectively. The corresponding overall
survival rates after diagnosis were 98%, 93%, 81%, 67%,
57% and 53%, respectively. In comparison, the expected
survival rates were 66%, 54%, 46%, 38%, 34% and 32%,
which was significantly lower than the observed overall
survival rates (p < 0.01).
Comparison of expected and observed survival after
initiation of intravenous iloprost
F i g u r e3s h o w st h eK a p l a n - M e i e rc u r v e so ft h eL u T x -
free survival (Figure 3a) and the overall survival (Figure
3b) following the initiation of continuous intravenous
iloprost therapy.
The probabilities for LuTx-free survival at 1, 2, 3, 4, 5
and 6 years were 38%, 27%, 17%, 17%, 17% and 17%,
respectively. In other words, 62% of these patients either
died or underwent LuTx within one year after initiation of
intravenous iloprost therapy. The observed overall survival
rates at these time points were 54%, 46%, 39%, 39%, 39%
and 39%. The median LuTx-free survival was 9 months
whereas the median overall survival was 15 months.
Predictors of survival
None of the parameters assessed at BL-Ilo was signifi-
cantly associated with survival by means of univariate
Figure 1 Available data of 6MWD for each patient at different
time points e.g. start of iloprost (BL-ilo), 3 months (3 Mo) and
12 months (12 Mo) after iloprost initiation. The median of the
6MWD increased from BL-ilo to 3 Mo and 12 Mo (289 m vs. 298 m
vs. 345 m). However, the between group differences were not
statistical significant (one-way ANOVA: p = 0.09)
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functional class IV at BL-Ilo had a median LuTx-free
survival of 6 months which did not differ significantly
from the 11 months seen in patients in functional class
III or better (p = 0.23, hazard ratio 1.5, 95% CI 0.77-
3.08).
Comparing survival curves of patients according to the
6MWD being more or less than 300 m did also show no
significant differences (data not shown). The median
LuTx-free survival was 11 months in patient walking >
3 0 0ma tB L - I l oc o m p a r e dt o1 0m o n t h si np a t i e n t s
walking < 300 m (p = 0.78, hazard ratio 1.13, 95% CI
0.49-2.56).
In contrast, the parameters obtained at 3 months after
initiation of intravenous iloprost treatment were more
useful in predicting outcomes (Figure 4a-d). All patients
who were in functional class IV after 3 months of ther-
apy died within one year. In contrast, patients in func-
tional class III after 3 months of therapy had a median
LuTx-free survival of 15 months (p = 0.01, hazard ratio
3.87, 95% CI 1.38-10.84).
Patients with a 6MWD < 300 m at month 3 had a
median LuTx-free survival of 8 months, whereas those
walking > 300 m had a significantly better prognosis
with a LuTx-free median survival of 19 months (p =
0.02, hazard ratio 3.14; 95% CI 1.17-8.45).
Line infections
In this cohort, 9 line infections were observed in 7
patients accounting for 0.41 cases of line infections per
1, 000 days of treatment.
Discussion
The present study casts doubts about the efficacy of
intravenous iloprost at least in the majority of cases
when added to IPAH patients who failed to respond
adequately to non-parenteral therapies. Only a small
subgroup of patients seemed to benefit from the intrave-
nous iloprost therapy. The overall survival rates 1, 3 and
5 years after diagnosis were 98%, 81%, and 57% which is
in accordance with outcome data reported from other
series [14-16]. However, once these patients failed non-
Figure 2 Kaplan-Meier curves showing the expected survival in comparison to the observed LuTx-free (A) and observed overall (LuTx
censored) (B) survival from the time of diagnosis. Patients at risk were n = 50, n = 47, n = 41, n = 32, n = 21, n = 16 and n = 14 at
diagnosis, 12, 24, 36, 48, 60 and 72 months after diagnosis (observed survival). Level of significance: LuTx-free survival vs. expected survival: p =
0.15. Overall survival vs. expected survival: p < 0.01. |: censored patients.
Figure 3 Kaplan-Meier curves showing the observed LuTx-free (A) and observed overall (B) survival from initiation of continuous
intravenous iloprost. Patients at risk n = 50, n = 16, n = 10, n = 6, n = 5, n = 5, n = 3 at BL-ilo, 12, 24, 36, 48, 60 and 72 months after
initiation of iloprost therapy (observed survival). |: censored patients.
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apparently little effects on 6MWD, functional class, and
survival. It is not possible to fully appraise the effects of
intravenous iloprost as there was no control group but
the fact that 62% of the patient died or required LuTx
within one year after this treatment was initiated is
troublesome. The worst outcome was seen in patients
remaining in functional class IV and/or having a
6MWD < 300 m after intravenous iloprost therapy had
been initiated.
The present data are in agreement with an earlier
report on the effects of intravenous iloprost as rescue
therapy in patients failing inhaled iloprost treatment [3].
In fact, the observed functional improvements as well as
the survival rates after initiation of intravenous iloprost
were even worse in the present series (e.g., LuTx-free
survival after 12 months 38% vs. 57% in the previous
series). The apparent poorer response of clinical and
functional parameters in the present study is most likely
a consequence of the pre-existing exhausted non-parent-
eral therapy.
Though parenteral prostanoids are used as salvage
treatment for patients failing other forms of therapy,
there is limited data to support this recommendation.
None of the available parenteral prostanoids has been
systematically studied as add-on therapy to non-parent-
eral combination therapy. The available data is currently
limited to non-controlled data from single centre studies
and most of these studies have used intravenous epo-
prostenol [17-19].
In a retrospective analysis of 36 patients receiving the
endothelin receptor antagonist bosentan, add-on admin-
istration of intravenous epoprostenol (n = 30) or inhaled
iloprost (n = 6) led to a significant increase in 6MWD
(347 m vs 310 m, p = 0.031) associated with an
improvement in functional class in 39% of cases [17].
T h em e a ne x p o s u r et ob o s e n t a nw a s1 2±1 0m o n t h s
prior to prostanoid therapy. The 1 and 2 year-survival
Figure 4 Kaplan-Meier curves demonstrating the impact of functional class (A and B) and 6MWD (C and D) 3 months after
introduction of intravenous iloprost on the LuTx-free and overall survival from the time point iloprost-start. LuTx-free survival: Hazard
ratio NYHA IV vs. III 3.87; 95% CI 1.38-10.84; Hazard ratio 6MWD < 300 m vs. > 300 m 3.14, 95% CI 1.17-8.45. Overall survival: Hazard ratio of
NYHA IV vs. NYHA III: 8.39, 95% CI 2.28-30.83; Hazard ratio of 6MWT < 300 m vs. > 300 m: 8.76, 95% CI 2.05-37.5. |: censored patients.
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71%, respectively [17].
Another series reported on 16 patients with IPAH
who received either intravenous epoprostenol (n = 6) or
subcutaneous (s.c.) treprostinil (n = 10) in addition to
bosentan monotherapy (n = 6) or bosentan/sildenafil
combination therapy (n = 10). The 6MWD at start of
prostanoid therapy was 363 ± 27 m and the mean inter-
val between start of oral therapy and start of prostanoids
was 21 ± 5 months. Improvements in 6MWD after 4
months were 86 m in the bosentan group versus 41 m
in the bosentan/sildenafil group. The difference between
both groups was not statistically significant. During a
median observation period of 18 months, there was only
one death and autopsy revealed that this patient suffered
from pulmonary veno-occlusive disease [18].
Finally, a series of 23 patients from Australia reported
on the use of epoprostenol as salvage therapy in patients
failing oral therapies (mostly monotherapy with either
bosentan or sildenafil; details and treatment durations
were not stated). In contrast to the previously discussed
series, epoprostenol was not added to the oral therapies
but replaced them. The reported improvement in
6MWD was 117 m (70-264 m; p = 0.002); three patients
died and 9 required transplantation [19].
It is difficult to compare these series with our data as
patient populations, selected therapies and treatment
durations varied substantially. The majority of patients
i nt h ep r e s e n ts t u d yw e r eo nd o u b l eo rt r i p l ec o m b i n a -
tion therapy and the median duration of non-parenteral
therapy was 34 months, i.e. longer than in the other ser-
ies. However, all other series reported on more substan-
tial functional improvements and apparently better
survival rates associated with parenteral prostanoid ther-
apy. It is possible that these differences resulted from
earlier use of parenteral therapy and/or from the fact
that non-parenteral therapy had not been fully
exhausted. However, another possible explanation for
the observed differences may be differences in efficacy
between iloprost and epoprostenol [20].
Although previous studies suggest similar effectiveness
of iloprost and epoprostenol [21,22], these two drugs
have never been formally compared in randomized clini-
cal trials. Intravenous iloprost, in fact, has never been
thoroughly studied in patients with IPAH and the fact
that it is widely used in Germany and some other Eur-
opean countries is related to the lack of approval of epo-
prostenol and some other historical reasons. It cannot
be ruled out that differences regarding effectiveness in
IPAH exist. Disturbing findings of the present study are
not only the low survival rates but also the apparent
lack of lasting clinical improvements in the vast majority
of our patients. It will be difficult, if not impossible, to
perform prospective large-scale trials comparing intrave-
nous epoprostenol and intravenous iloprost. A possible
w a yt od e r i v es o m ed a t aa d d r e s s i n gt h eq u e s t i o n
whether epoprostenol is or is not more efficacious than
iloprost might be to switch patients not responding suf-
ficiently from intravenous iloprost to epoprostenol.
We cannot rule out insufficient dosing of iloprost as a
contributing factor in the present study. The mean ilo-
prost dose at 12 months (1.9 ng/min/kg) was lower than
in our previous study (2.6 ng/min/kg after 6 months)
[3]. However, all centres attempted to up titrate iloprost
to the highest tolerated dose and there was no associa-
tion between iloprost dose and changes in 6MWD.
One may also argue that intravenous iloprost therapy
was initiated too late in the present population. Earlier
initiation of therapy is likely to be associated with better
survival rates but it is unclear whether this is caused by
length bias or by a true survival effect. So far, no study
has shown that earlier use of parenteral prostanoid ther-
apy in patients with IPAH results in better long-term
outcome.
Complications related to the delivery system appeared
to be similar to other series and are therefore unlikely
to be responsible for the present findings. In our cohort
we observed 0.41 cases of line infections per 1, 000 days
of treatment which is in line with previous studies
reporting a rate of catheter-infections per 1, 000 treat-
ment-days between 0.26 [23] and 0.42 [24], respectively,
for epoprostenol, and 1.13 for treprostinil [24].
The present study has several important limitations
including the relatively small number of patients, the
lack of a control group, the retrospective design and the
abundance of missing data. In addition, there was no
formal study protocol and no pre-established criteria for
starting and dosing intravenous therapy. All these lim-
itations reflect the fact that our data was not derived
from a prospective clinical trial but from clinical experi-
ence. Therefore, despite lacking robustness, our data
represent real-life scenarios.
Conclusion
The clinical effect of adding intravenous iloprost to
IPAH patients failing on extensive non-parenteral ther-
apy appears to be modest, and failed to prevent death or
transplantation in the majority of patients. Despite all
limitations, our data suggest that the role of i.v. prosta-
noid therapy in the era of oral and inhalative treatments
for IPAH needs to be redefined. In pre-treated patients
timing and choice of i.v. prostanoid therapy needs to be
reconsidered and should be further addressed in dedi-
cated clinical trials. Finally, these results underline the
need for the development of new agents out of new
classes of drugs in this therapeutic indication.
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